Drug analysis: Stivarga

  • ID: 4462150
  • Drug Pipelines
  • 28 pages
  • Datamonitor Healthcare
1 of 3
Drug Overview

Stivarga (regorafenib; Bayer/Amgen) is a novel diphenylurea oral multikinase inhibitor of angiogenic (vascular endothelial growth factor receptor [VEGFR], platelet-derived growth factor receptor [PDGFR], and fibroblast growth factor receptor [FGFR]), stromal, and oncogenic (KIT, RET, and B-Raf) kinases. VEGF-directed agents are a key target in colorectal cancer following the success of Avastin (bevacizumab; Genentech/Roche/Chugai). The anti-angiogenic effect of Stivarga was demonstrated in vivo by dynamic contrast-enhanced magnetic resonance imaging (MRI). In such in vivo models, Stivarga demonstrated anti-angiogenic activity in animal tumor models, inhibition of tumor growth, and antimetastatic activity. A significant reduction in tumor microvessel area was observed in a human colorectal xenograft after dosing.
Note: Product cover images may vary from those shown
2 of 3
Product Profiles
Stivarga: Colorectal cancer (CRC)
Stivarga: Hepatocellular carcinoma (HCC)

List of Figures
Figure 1: Stivarga for colorectal cancer - SWOT analysis
Figure 2: Drug assessment summary of Stivarga for colorectal cancer
Figure 3: Drug assessment summary of Stivarga for colorectal cancer
Figure 4: Stivarga sales for colorectal cancer across the US, Japan, and five major EU markets, by country, 2016-25
Figure 5: Stivarga for HCC - SWOT analysis
Figure 6: Drug assessment summary of Stivarga for HCC
Figure 7: Drug assessment summary of Stivarga for HCC

List of Tables
Table 1: Stivarga drug profile
Table 2: Stivarga pivotal trial data in colorectal cancer
Table 3: Stivarga ongoing trials in colorectal cancer
Table 4: Stivarga sales for colorectal cancer across the US, Japan, and five major EU markets, by country ($m), 2016-25
Table 5: Patients treated with Stivarga across the US, Japan, and five major EU markets, by country, 2016-25
Table 6: Stivarga drug profile
Table 7: Stivarga pivotal trial data in HCC
Table 8: Stivarga Phase II data in HCC
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll